While Aquestive Therapeutics Inc has overperformed by 6.70%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AQST rose by 217.39%, with highs and lows ranging from $6.23 to $1.15, whereas the simple moving average jumped by 82.16% in the last 200 days.
On April 11, 2024, Piper Sandler started tracking Aquestive Therapeutics Inc (NASDAQ: AQST) recommending Overweight. A report published by Raymond James on March 28, 2024, Initiated its previous ‘Outperform’ rating for AQST. RBC Capital Mkts also rated AQST shares as ‘Outperform’, setting a target price of $7 on the company’s shares in an initiating report dated April 07, 2021. Lake Street initiated its ‘Buy’ rating for AQST, as published in its report on January 03, 2019. RBC Capital Mkts’s report from August 20, 2018 suggests a price prediction of $23 for AQST shares, giving the stock a ‘Outperform’ rating. JMP Securities also rated the stock as ‘Mkt Outperform’.
Analysis of Aquestive Therapeutics Inc (AQST)
Further, the quarter-over-quarter increase in sales is 23.63%, showing a positive trend in the upcoming months.
One of the most important indicators of Aquestive Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 1.87, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and AQST is recording 2.45M average volume. On a monthly basis, the volatility of the stock is set at 7.87%, whereas on a weekly basis, it is put at 9.38%, with a gain of 11.17% over the past seven days. Furthermore, long-term investors anticipate a median target price of $9.00, showing growth from the present price of $4.38, which can serve as yet another indication of whether AQST is worth investing in or should be passed over.
How Do You Analyze Aquestive Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.31%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 26.34% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AQST shares are owned by institutional investors to the tune of 26.34% at present.
